Does Walgreen have the cure for what ails investors?
CEO Gregory Wasson's turnaround has been successful.
Investors in Walgreen Co. (WAG) don't need a spoonful of sugar to help the medicine go down because returns from the largest drugstore operator have been plenty sweet.
Shares of the largest drugstore chain have surged more than 50 percent this year as Chief Executive Gregory Wasson's turnaround has taken hold. Along with improving the company’s fresh food and beauty offerings, Wasson has implemented a successful loyalty card program and pushed the company further into the wellness business.
During the most recent quarter, Walgreen posted solid results. Net income surged 86 percent to $657 million, or 69 cents per share, from $353 million, or 39 cents, a year earlier. Excluding one-time items, profit was 73 cents, a penny better than analysts’ expectations. Revenue rose 5.1% to $17.94 billion, slightly under the $17.95 billion analysts had forecast. Shares closed Tuesday at $56.24.
Sales at stores opened at least a year, a key retail metric, rose an impressive 4.6% even as customer traffic fell 1.9 percent. Comparable sales improved even more in September. The company benefited from increased sales of generic drugs, which carry higher margins and lower prices than their brand name counterparts. Revenue in the front of the store, which had been a weak spot, gained 1.6 percent in the quarter and jumped 6.4 percent in pharmacy department. Walgreeen's 45 percent stake in U.K.-based Alliance Boots also is paying off.
Walgreen is also well positioned for Obamacare, which opened its online exchanges yesterday. The company has also been adding primary health care services such as immunizations, which will attract some of the millions of uninsured people who will soon get coverage under the law. Customers at 350 stores can get treated for minor aches and pains by the chain’s nurse practioners.
Though shares of Walgreen have a spring in their step, they are kind of pricy, so there is no sense of urgency to buy them. They trade at a price-to-earnings ratio of 23.68, a five-year high, according to Reuters. They are trading above their average 52-week price target of $54.31. Some analysts think Walgreen will climb higher. Analysts at Morgan Stanley (MS) have raised their price target on the stock to $70.
Given the uncertainties around the stock, investors should take a pass on the shares until there is a pull back in the price.
Follow Jonathan Berr on Twitter @jdberr or on Berr's World.
More from Top Stocks
Copyright © 2013 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.
The offering could become the second-biggest this year if underwriters exercise an option to buy more shares.
VIDEO ON MSN MONEY
Top Stocks provides analysis about the most noteworthy stocks in the market each day, combining some of the best content from around the MSN Money site and the rest of the Web.
Contributors include professional investors and journalists affiliated with MSN Money.
Follow us on Twitter @topstocksmsn.